Pharmacokinetic interactions between buprenorphine and antiretroviral medications (Q36655057)

15 August 2017

1 reference

title

Pharmacokinetic interactions between buprenorphine and antiretroviral medications (English)

1 reference

15 August 2017

anti-retroviral agent

0 references

1 reference

3

Evan D Kharasch

1 reference

15 August 2017

R Douglas Bruce

1

1 reference

15 August 2017

Elinore McCance-Katz

series ordinal

2

1 reference

15 August 2017

David E Moody

series ordinal

4

1 reference

15 August 2017

Gene D Morse

series ordinal

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Clinical Infectious Diseases

15 August 2017

1 reference

15 August 2017

43 Suppl 4

1 reference

15 August 2017

S216-23

1 reference

In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

15 August 2017

1 reference

A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies

21 January 2018

1 reference

The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1

21 January 2018

1 reference

Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8.

21 January 2018

1 reference

Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites

21 January 2018

1 reference

21 January 2018

Buprenorphine kinetics

1 reference

Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis

21 January 2018

1 reference

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations

21 January 2018

1 reference

Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms

21 January 2018

1 reference

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine

21 January 2018

1 reference

Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naı̈ve healthy male volunteers under a naltrexone block

21 January 2018

1 reference

Relative bioavailability of different buprenorphine formulations under chronic dosing conditions

21 January 2018

1 reference

The systemic availability of buprenorphine administered by nasal spray

21 January 2018

1 reference

Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification

21 January 2018

1 reference

Evaluation of an injection depot formulation of buprenorphine: placebo comparison

21 January 2018

1 reference

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine

21 January 2018

1 reference

Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir

21 January 2018

1 reference

Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.

21 January 2018

1 reference

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

21 January 2018

1 reference

Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies

21 January 2018

1 reference

Interactions between recreational drugs and antiretroviral agents

21 January 2018

1 reference

Buprenorphine: how to use it right

21 January 2018

1 reference

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey

21 January 2018

1 reference

Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil

21 January 2018

1 reference

The implications of P-glycoprotein in HIV: friend or foe?

21 January 2018

1 reference

The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone

21 January 2018

1 reference

Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl

21 January 2018

1 reference

Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine

21 January 2018

1 reference

Buprenorphine: considerations for pain management

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics

21 January 2018

1 reference

Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence

21 January 2018

1 reference

Six deaths linked to concomitant use of buprenorphine and benzodiazepines

21 January 2018

1 reference

A new series of 13 buprenorphine-related deaths

21 January 2018

1 reference

Buprenorphine and midazolam act in combination to depress respiration in rats

21 January 2018

1 reference

Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes

21 January 2018

1 reference

Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/508186

1 reference

15 August 2017

1 reference